Replies to post #95630 on Biotech Values

[DewDiligence]

A caption in VRUS' PR about seeking an acquisition is something I personally feel is of no interest to them.

The language you’re referring to is boilerplate stuff that one sees in almost every financing announcement. From the link in #msg-50043109:

Pharmasset intends to use the net proceeds from the sale of the shares for general corporate purposes, which may include, but are not limited to, the funding of clinical trials, the funding of in-licensing agreements for product candidates, additional technologies or other forms of intellectual property and the acquisition of assets or businesses that are complementary to its existing business.

The above paragraph has zero utility for investors, IMO.

VRUS obviously wants top dollar for their 2ND-generation nuke [PSI-7977] but the danger is if they ask too much Roche may choose to go hostile. It would be a quick gain for most VRUS shareholders but a potentially huge loss in long term value from this small company going forward.

The devil is in the details. VRUS has an unduly high valuation already, IMO; it follows that I think a typical buyout premium to the current share price would be an excellent deal for VRUS shareholders.

If you could expand on those rumor reports…

“Reports” is too strong a word—all I’ve seen are random comments on message boards from time to time. Regards, Dew